476 related articles for article (PubMed ID: 29957022)
1. New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.
Davel AP; Jaffe IZ; Tostes RC; Jaisser F; Belin de Chantemèle EJ
Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H989-H999. PubMed ID: 29957022
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid Receptor and Cardiovascular Disease.
Buonafine M; Bonnard B; Jaisser F
Am J Hypertens; 2018 Oct; 31(11):1165-1174. PubMed ID: 30192914
[TBL] [Abstract][Full Text] [Related]
3. New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention.
Kolodziejczyk P; Gromotowicz-Poplawska A; Aleksiejczuk M; Chabielska E; Tutka P; Miltyk W
Curr Drug Targets; 2018; 19(16):1968-1979. PubMed ID: 29577853
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoids in the heart and vasculature: new insights for old hormones.
Lother A; Moser M; Bode C; Feldman RD; Hein L
Annu Rev Pharmacol Toxicol; 2015; 55():289-312. PubMed ID: 25251996
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
Funder JW
Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
[TBL] [Abstract][Full Text] [Related]
6. The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall.
Jia G; Aroor AR; Sowers JR
Cardiovasc Res; 2017 Jul; 113(9):1055-1063. PubMed ID: 28838041
[TBL] [Abstract][Full Text] [Related]
7. Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.
Chrissobolis S
Curr Hypertens Rev; 2017; 13(1):46-56. PubMed ID: 28245785
[TBL] [Abstract][Full Text] [Related]
8. Emerging vascular cell-specific roles for mineralocorticoid receptor: implications for understanding sex differences in cardiovascular disease.
Wolter NL; Jaffe IZ
Am J Physiol Cell Physiol; 2023 Jan; 324(1):C193-C204. PubMed ID: 36440858
[TBL] [Abstract][Full Text] [Related]
9. Does Aldosterone Play a Significant Role for Regulation of Vascular Tone?
Lyngsø KS; Assersen K; Dalgaard EG; Skott O; Jensen BL; Hansen PB
J Cardiovasc Pharmacol; 2016 Jul; 68(1):1-10. PubMed ID: 26657712
[TBL] [Abstract][Full Text] [Related]
10. Role of mineralocorticoid receptor antagonists in cardiovascular disease.
Ferrario CM; Schiffrin EL
Circ Res; 2015 Jan; 116(1):206-13. PubMed ID: 25552697
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease.
Gorini S; Marzolla V; Mammi C; Armani A; Caprio M
Biomolecules; 2018 Sep; 8(3):. PubMed ID: 30231508
[TBL] [Abstract][Full Text] [Related]
12. Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.
Nagase M
Clin Exp Nephrol; 2010 Aug; 14(4):303-14. PubMed ID: 20533072
[TBL] [Abstract][Full Text] [Related]
13. Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries.
Sztechman D; Czarzasta K; Cudnoch-Jedrzejewska A; Szczepanska-Sadowska E; Zera T
J Physiol Pharmacol; 2018 Dec; 69(6):. PubMed ID: 30898981
[TBL] [Abstract][Full Text] [Related]
14. [Antifibrotic renal role of mineralcorticoid receptor antagonists].
Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A
G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology.
Cannavo A; Bencivenga L; Liccardo D; Elia A; Marzano F; Gambino G; D'Amico ML; Perna C; Ferrara N; Rengo G; Paolocci N
Oxid Med Cell Longev; 2018; 2018():1204598. PubMed ID: 30327709
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in the time course and mechanisms of vascular and cardiac aging in mice: role of the smooth muscle cell mineralocorticoid receptor.
DuPont JJ; Kim SK; Kenney RM; Jaffe IZ
Am J Physiol Heart Circ Physiol; 2021 Jan; 320(1):H169-H180. PubMed ID: 33095647
[TBL] [Abstract][Full Text] [Related]
17. The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease.
Moss ME; Carvajal B; Jaffe IZ
Pharmacol Ther; 2019 Nov; 203():107387. PubMed ID: 31271793
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
Kolkhof P; Joseph A; Kintscher U
Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
Whaley-Connell A; Johnson MS; Sowers JR
Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958
[TBL] [Abstract][Full Text] [Related]
20. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease.
Funder JW
Am J Cardiovasc Drugs; 2007; 7(3):151-7. PubMed ID: 17610342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
